The Supreme Court on Tuesday (November 21) reprimanded the Patanjali Ayurved for continuing to publish misleading claims and advertisements against modern systems of medicine.
While considering a petition filed by the Indian Medical Association against misleading advertisements, the bench comprising Justices Ahsanuddin Amanullah and Prashant Kumar Mishra issued a stern warning to the company co-founded by Baba Ramdev.
“All such false and misleading advertisements of Patanjali Ayurved have to stop immediately. The Court will take any such infraction very seriously, and the Court will also consider imposing costs to the extent of Rs. 1 crores on every product regarding which a false claim is made that it can “cure” a particular disease,” Justice Amanullah orally said.
The bench observed during the hearing that it did not wish to make the issue an “Allopathy v. Ayurveda” debate but wanted to find a real solution to the problem of misleading medical advertisements.
Stating that it is examining the issue seriously, the bench told Additional Solicitor General of India KM Nataraj that the Union Government will have to find a viable solution to tackle the problem. The Government was asked to come up with suitable recommendations after consultations. The matter will be considered next on February 5, 2024.
Last year, while issuing notice on the IMA’s petition, the Court had pulled up Baba Ramdev for making statements against modern medicine systems like Allopathy.
The IMA contends that while every commercial entity has the right to promote its products, the unverified claims made by Patanjali are in direct violation of laws such as the Drugs & Other Magic Remedies Act, 1954, and the Consumer Protection Act, 2019.
The IMA further accuses Patanjali of spreading false rumors about COVID-19 vaccines and contributing to vaccine hesitancy. Swami Ramdev’s alleged mockery and derision of citizens searching for oxygen cylinders during the second wave are also cited in the petition.
The petition emphasizes that despite the Ministry of AYUSH signing a Memorandum of Understanding (MoU) with the Advertising Standards Council of India (ASCI) for monitoring misleading advertisements of AYUSH drugs, Patanjali has continued its alleged disregard for the law, violating the mandate with impunity.
